OakChart

Kiora Pharmaceuticals Inc

KPRXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.35-0.03 (-2.17%)
2026-11-12 00:26 CET
Market cap
6.11 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-10.99 USD m
Free cash flow, TTM
-8.61 USD m
EPS diluted, TTM
-2.64
P/E
-
Compare

Price

KPRX against its 20, 50 and 200-day averages
2050200beat
1.502.002.50245K491KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KPRXclose 1.3520-day 1.9450-day 2.33200-day 2.391.3552w high

53.6% under the 52-week high of 2.91 on 8 Apr 2026. 52-week low 1.33 on 11 Nov 2026. Last 15 sessions, 93.2% high to low

Volume 0.69× normal · the line is the 50-bar volume average

Profile

KPRX
52-week range, 0% of the way up
1.372.91

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Employees13
IPOFeb 13, 2015
Beta-0.13
ATR, 14d0.15
Rel volume0.69
Short float1.45%
Insider own11.64%
Inst own36.01%

Snapshot

6 groups

Valuation

Index-
Market Cap5.98M
Enterprise Value-10.53M
Income-10.99M
Sales0.00M
Book/sh3.81
Cash/sh3.80
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees13
IPOFeb 13, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.35
P/C0.35
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio8.97
Current Ratio8.97
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.64
EPS next Y-0.79
EPS next Q-0.38
EPS this Y56.82%
EPS next Y30.70%
EPS next 5Y28.38%
EPS past 3/5Y75.03% 65.58%
Sales past 3/5Y- -
EPS Y/Y TTM19.38%
Sales Y/Y TTM-100.00%
EPS Q/Q37.64%
Sales Q/Q-
EarningsAug 07 BMO
EPS/Sales Surpr.27.66% -

Ownership

Insider Own11.64%
Insider Trans0.00%
Inst Own36.01%
Inst Trans17.00%
ROA-39.43%
ROE-56.36%
ROIC-64.56%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-30.52%
SMA50-42.05%
SMA200-43.45%
Trades-

Technical

Shs Outstand4.43M
Shs Float3.91M
Short Float1.45%
Short Ratio1.89
Short Interest0.06M
52W High2.91 -53.61%
52W Low1.37 -1.46%
Volatility9.67% 7.99%
ATR (14)0.15
RSI (14)23.18
Beta-0.13
Rel Volume0.69
Avg Volume29.95K
Volume20,539

Performance

Perf Week-18.67%
Perf Month-45.34%
Perf Quarter-47.88%
Perf Half Y-49.81%
Perf YTD-31.47%
Perf Year-41.05%
Perf 3Y-76.32%
Perf 5Y-99.75%
Perf 10Y-99.98%
Recom1.00
Target Price12.00
Prev Close1.38
Price1.35
Change %-2.17%

Peers

Mkt cap
TickerCompanyMkt cap
IRDOpus Genetics Inc358.58M
KALAKala Bio Inc3.31M
ALDXAldeyra Therapeutics Inc39.32M
OKYOOKYO Pharma Limited74.52M
BLTEBelite Bio Inc ADR6.28B
EYPTEyePoint Inc30.74M
OCSOculis Holding AG469.78M
OCULOcular Therapeutix Inc1.47B
LENZLENZ Therapeutics Inc129.13M
SGPSpyGlass Pharma Inc1.17B

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 665.71M
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B

News

latest 14 of 198

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-07-0.340-0.470-0.3400.00-1
2026Q12026-05-08-0.580-0.710-0.5790.001.501
2025Q42026-03-27-1.590-0.670-1.7321.501.501
2025Q32025-11-070.010-0.7350.0060.000.752
2025Q22025-08-08-0.540-0.605-0.5400.000.752
2025Q12025-05-09-0.520-0.670-0.5200.000.752
2024Q42025-03-25-1.210-0.550-1.4080.000.752
2024Q32024-11-08-0.810-0.763-0.8100.000.013
2024Q22024-08-09-0.530-0.857-0.5330.020.003
2024Q12024-05-103.4202.4753.45716.0016.002
2023Q42024-03-25-2.550-3.510-2.6500.000.003
2023Q32023-11-13-7.770-4.680-7.9710.00-3
2023Q22023-08-08-7.110-9.585-7.151--2
2023Q12023-05-09-9.000-15.165-9.0250.000.003
2022Q42023-03-23-17.070-22.140-12.5170.000.003
2022Q32022-11-09-54.270-34.515-54.2980.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-802.8-752.4-803.142.692.69
2020FY-637.2-727.2-5380.000.03
2021FY-637.2-446.4-514.050.000.00
2022FY-166.95-172.49-166.94-0.00
2023FY-24.210-23.280-24.2470.000.00
2024FY0.8700.8650.87116.0216.76
2025FY-2.640-1.710-2.6001.501.50
2026FY--1.140---
2027FY--0.790---
2028FY--0.970---
2029FY--1.120--56.53
2030FY--1.250--52.90

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00
2026Q3S2025-11-021000.000.000.00
2026Q3S2025-11-011000.000.000.00
2026Q3S2025-10-311000.000.000.00
2026Q3S2025-10-301000.000.000.00
2026Q3S2025-10-291000.000.000.00
2026Q3S2025-10-281000.000.000.00
2026Q3S2025-10-271000.000.000.00

Estimate history

EPS, annual-5022-1645.326-803.142-538.002-514.048-166.943-24.2470.871-2.6-2.6419
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.533-0.81-1.408-0.52-0.540.006-1.732-0.579-0.337
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.4081.6532.6860.01200016.0200
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0200000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0030.0080.0110.0150.0350.20.8563.0013.7624.427
Period201720182019202020212022202320242025MRQ
Shares, quarterly2.9713.0013.0013.0013.4333.4333.7623.9934.427
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.0016.020.000.000.000.012.691.65
Cost of Goods Sold Incl. D&A0.140.020.070.060.130.230.20--
Gross Profit-0.14-0.0215.95-0.06-0.13-0.23-0.19--
Selling, General and Administrative Excl. Other9.639.4313.328.6311.5910.317.619.5812.46
Research and Development3.883.717.844.033.455.353.575.398.06
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-9.77-9.462.64-8.69-11.73-10.53-7.80-7.11-10.84
Interest Expense0.000.000.020.010.010.010.000.000.00
Unusual Expense3.063.371.173.902.013.42-0.82--
Net Income Before Taxes-12.28-12.125.66-12.42-13.70-13.96-6.85-7.00-10.73
Income Taxes-1.29-1.282.070.09-0.11-0.190.010.100.09
Consolidated Net Income-10.99-10.843.59-12.51-13.58-13.77-6.86-7.10-10.81
Net Income From Continuing Operations-10.99-10.843.59-12.51-13.58-13.77-6.86-7.10-10.81
Net Income-10.99-10.843.59-13.04-13.58-13.77-6.86-7.10-10.81
EPS (Recurring)-1.43-2.031.07-19.18-149.67-424.59-582.80-803.14-1,645.31
EPS (Basic, Before Extraordinaries)-2.64-2.600.93-24.25-166.94-514.05-538.00-803.14-1,645.33
EPS (Diluted)-2.64-2.600.87-24.25-166.94-514.05-538.00-803.14-1,645.33
EBITDA-9.63-9.432.70-8.63-11.59-10.31-7.60-6.90-10.81
Non-Operating Income (Expense)0.550.714.220.170.050.000.140.110.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.710.710.520.600.370.620.530.620.69
Price To Sales Ratio--0.85---1,877.1111.879.99
Gross Margin--99.59----1,560.34--
Operating Margin--16.45----64,671.66-264.67-656.25
Net Margin--22.44----56,901.65-264.21-654.24
Shares Outstanding4.433.763.000.860.200.040.020.010.01
Market Capitalization6.116.119.904.023.7019.1227.3940.8620.37

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.050.040.010.040.030.020.020.01
Gross Profit-0.05-0.04-0.01-0.04-0.03-0.02-0.02-0.01
Selling, General and Administrative Excl. Other2.072.462.622.482.232.045.432.68
Research and Development0.740.891.171.070.900.574.121.32
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.12-2.50-2.63-2.52-2.26-2.06-5.45-2.70
Interest Expense0.000.000.000.00-0.00-0.00
Unusual Expense0.090.014.68-1.720.140.280.160.90
Net Income Before Taxes-2.08-2.42-7.17-0.62-2.26-2.07-2.16-3.41
Income Taxes0.000.00-0.65-0.64-0.110.122.070.00
Consolidated Net Income-2.08-2.42-6.520.03-2.15-2.19-4.22-3.41
Net Income From Continuing Operations-2.08-2.42-6.520.03-2.15-2.19-4.22-3.41
Net Income-2.08-2.42-6.520.03-2.15-2.19-4.22-3.41
EPS (Recurring)-0.33-0.58-0.86-0.27-0.52-0.47-1.37-0.66
EPS (Basic, Before Extraordinaries)-0.34-0.58-1.730.01-0.54-0.52-1.41-0.81
EPS (Diluted)-0.34-0.58-1.730.01-0.54-0.52-1.41-0.81
EBITDA-2.07-2.46-2.62-2.48-2.23-2.04-5.43-2.68
Non-Operating Income (Expense)0.130.090.140.180.130.263.460.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.110.210.190.200.210.120.130.17
Price To Earnings Ratio-----4.26--
Price To Sales Ratio-----634.660.620.96
Shares Outstanding4.433.993.763.433.433.003.003.00
Market Capitalization6.117.627.259.558.779.039.9010.87

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments17.0926.792.455.967.851.193.788.007.81
Short Term Receivables3.320.872.051.370.530.090.000.020.02
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.342.040.230.340.610.450.540.460.63
Total Current Assets21.7529.714.747.688.991.734.328.488.46
Net Property, Plant & Equipment0.380.060.110.170.280.110.020.040.06
Total Investments and Advances0.000.000.000.050.040.040.040.040.04
Long-Term Note Receivable--------0.00
Intangible Assets2.066.698.8110.7410.7713.365.665.685.44
Other Assets0.060.020.040.030.040.060.070.030.31
Total Assets24.2536.4813.7118.6820.1315.3010.1114.2814.31
Short Term Debt Incl. Current Port. of LT Debt0.160.020.050.110.120.260.080.000.01
Accounts Payable1.060.420.211.010.000.000.210.060.71
Income Tax Payable0.142.33-------
Other Current Liabilities2.263.241.382.161.491.721.123.8014.12
Total Current Liabilities3.636.011.633.271.611.981.413.8614.83
Long Term Debt0.200.030.060.000.090.310.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.100.490.780.690.800.730.370.270.18
Other Liabilities4.194.195.133.313.052.551.711.211.21
Total Liabilities8.1310.727.607.275.555.573.495.3416.23
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value4E-064E-064E-060.000.000.000.000.006E-06
Common Equity16.1325.766.1111.4114.589.736.628.94-1.93
Total Shareholders Equity16.1325.766.1111.4114.589.736.628.94-1.93
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity16.1325.766.1111.4114.589.736.628.94-1.93
Total Liabilities & Stockholders Equity24.2536.4813.7118.6820.1315.3010.1114.2814.31
Book Value Per Share4.298.587.1457.15414.44630.39584.651,101.88-602.96
Tangible Book Value Per Share3.746.36-3.163.33108.33-235.3085.23401.27-2,304.64
Full-Time Employees131212121414101117
Price to Book Ratio0.360.330.500.351.313.916.172.2827.09
Return on Assets-35.6814.32-77.27-70.00-78.05-53.99-58.19-75.64-109.72
Return on Equity-51.7422.56-142.88-104.54-127.63-83.92-91.22-308.49-
Return on Invested Capital-66.3513.94-202.84-119.08-93.87-68.32-107.16-120.98-
Quick Ratio5.994.942.902.355.590.873.062.190.57
Current Ratio5.994.942.902.355.590.873.062.190.57

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-10.99-10.843.59-12.51-13.58-13.77-6.86-7.10-10.81
Depreciation0.070.020.070.060.130.230.200.210.04
Other Funds (Non Cash)4.204.511.524.632.474.10-0.351.350.88
Funds from Operations-7.10-6.694.89-7.73-11.10-9.64-7.00-5.44-9.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.40-3.273.67-1.820.67-1.04-0.32-2.72-1.03
Cash from Operating Activities-8.51-9.968.56-9.56-10.43-10.68-7.32-8.15-10.84
Capital Expenditures-0.11-0.11-0.010.000.00-0.06-0.020.00-0.27
Net Assets From Acquisitions0.000.000.000.000.00-0.09-0.220.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.010.000.000.00-
Purchase or Sale of Investments9.7114.54-22.660.000.000.000.000.000.00
Purchase of Investments-9.12-8.18-35.630.000.000.000.000.00-
Sale Or Maturity of Investments18.8322.7112.980.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities9.6014.43-22.660.000.01-0.16-0.240.00-0.27
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock4.930.2715.506.468.6217.804.723.9311.31
Repurchase of Common Pref Stock0.000.000.000.00-0.020.000.00-0.000.00
Sale of Common Pref Stock4.930.2715.506.468.6417.804.723.9311.31
Proceedsfrom Stock Options4.930.0013.816.158.1217.754.501.7810.11
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.28-0.00-0.01
Change in Long Term Debt0.000.000.000.000.000.000.28-0.00-0.01
Issuance of Long Term Debt0.000.000.000.000.000.000.280.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-0.00-0.01
Net Financing Active Other Cash Flow-0.010.000.00-0.490.000.000.000.000.00
Other Financing Activities Uses-0.010.000.00-0.490.000.000.000.000.00
Cash from Financing Activities4.920.2715.505.978.6217.585.003.9211.30
Exchange Rate Effect0.040.17-0.060.04-0.09-0.08-0.030.010.01
Net Change in Cash6.054.901.34-3.55-1.896.67-2.59-4.230.20
Free Cash Flow-8.61-10.078.55-9.56-10.43-10.74-7.34-8.15-10.86
Preferred Dividends (Cash Flow)----0.000.00---
Price to Free Cash Flow--1.59------
Deferred Taxes & Investment Tax Credit--0.39-0.290.09-0.11-0.190.010.100.09

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments16.8413.8717.0919.3820.6724.11
Short Term Receivables2.913.453.322.673.112.06
Inventories0.000.000.000.000.000.00
Other Current Assets1.521.361.340.650.960.94
Total Current Assets21.2618.6821.7522.6924.7427.11
Net Property, Plant & Equipment0.360.390.380.420.460.16
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.062.062.066.696.696.69
Other Assets0.090.090.060.060.060.06
Total Assets23.7821.2324.2529.8631.9534.02
Short Term Debt Incl. Current Port. of LT Debt0.170.180.160.160.140.07
Accounts Payable0.220.591.060.240.280.94
Income Tax Payable0.070.090.140.000.922.46
Other Current Liabilities1.921.932.262.181.841.80
Total Current Liabilities2.372.803.632.583.195.27
Long Term Debt0.160.200.200.250.290.09
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.100.100.100.490.490.49
Other Liabilities4.294.204.194.135.854.47
Total Liabilities6.927.298.137.459.8210.32
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value4E-064E-064E-064E-064E-064E-06
Common Equity16.8613.9316.1322.4122.1323.70
Total Shareholders Equity16.8613.9316.1322.4122.1323.70
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity16.8613.9316.1322.4122.1323.70
Total Liabilities & Stockholders Equity23.7821.2324.2529.8631.9534.02
Book Value Per Share3.813.494.296.536.447.90
Tangible Book Value Per Share3.342.973.744.584.505.67
Full-Time Employees--13---
Price to Book Ratio0.360.450.300.430.360.35
Return on Assets-39.43-40.04-35.68-24.99-32.94-31.52
Return on Equity-56.36-58.78-51.74-32.58-43.39-41.13
Return on Invested Capital-12.22-17.11-39.900.12-9.60-9.22
Quick Ratio8.976.685.998.797.765.14
Current Ratio8.976.685.998.797.765.14

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.08-2.42-6.520.03-2.15-2.19
Depreciation0.050.04-0.060.040.030.02
Other Funds (Non Cash)0.210.285.14-1.430.390.40
Funds from Operations-1.82-2.10-1.83-1.36-1.73-1.77
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.07-1.06-0.350.09-2.07-0.93
Cash from Operating Activities-1.89-3.16-2.18-1.27-3.80-2.70
Capital Expenditures-0.02-0.01-0.08-0.00-0.030.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-6.875.415.435.740.702.67
Purchase of Investments-9.120.000.000.00-4.56-3.62
Sale Or Maturity of Investments2.265.415.435.745.256.29
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-6.895.405.355.740.662.67
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.00--
Change in Capital Stock4.930.000.000.000.270.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.930.000.000.000.270.00
Proceedsfrom Stock Options4.930.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.01-0.000.000.000.000.00
Other Financing Activities Uses-0.01-0.000.000.000.000.00
Cash from Financing Activities4.92-0.000.000.000.270.00
Exchange Rate Effect-0.020.020.020.010.130.01
Net Change in Cash-3.882.263.194.48-2.74-0.02
Free Cash Flow-1.92-3.17-2.26-1.27-3.84-2.70

Revenue breakdown

Pharmaceutical Preparations2024: 16.02M
United States2024: 16.02M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.45%0.1M3.9M24.16K
2026-10-150.11%0.0M3.9M17.28K
2026-09-300.09%0.0M3.9M17.01K
2026-09-150.10%0.0M3.9M19.59K
2026-08-310.08%0.0M4.2M21.32K
2026-08-140.07%0.0M4.2M24.43K
2026-07-310.09%0.0M4.2M36.99K
2026-07-150.20%0.0M4.2M38.76K
2026-06-300.17%0.0M4.2M489.98K
2026-06-150.50%0.0M4.2M483.67K
2026-05-290.44%0.0M4.1M491.60K
2026-05-150.53%0.0M4.2M489.93K
2026-04-300.83%0.0M3.7M491.31K
2026-04-150.80%0.0M3.6M510.31K
2026-03-310.47%0.0M3.6M47.38K
2026-03-130.47%0.0M3.4M46.00K
2026-02-270.24%0.0M3.4M48.50K
2026-02-130.26%0.0M3.4M54.66K
2026-01-300.40%0.0M3.4M51.54K
2026-01-150.77%0.0M3.4M43.22K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-298-KCurrent report2026-10-23SEC
2026-09-17SCHEDULE 13GSEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-173Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-198-KCurrent report2026-08-19SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-10SCHEDULE 13GSEC
2026-08-078-KCurrent report2026-08-07SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-188-KCurrent report2026-06-18SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-118-KCurrent report2026-06-10SEC
2026-05-28424B3SEC
2026-05-22EFFECTEffectiveness filing by commission orderSEC
2026-05-20CORRESPSEC
2026-05-20UPLOADUpload SubmissionSEC
2026-05-18S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-088-KCurrent report2026-05-08SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
PERCEPTIVE ADVISORS LLC9.89%
ADAR1 Capital Management, LLC3.79%
CITADEL ADVISORS LLC2.62%
TWO SIGMA INVESTMENTS, LP2.00%
MILLENNIUM MANAGEMENT LLC1.67%
HRT FINANCIAL LP1.32%
GEODE CAPITAL MANAGEMENT, LLC1.04%
RENAISSANCE TECHNOLOGIES LLC0.67%
VANGUARD CAPITAL MANAGEMENT LLC0.45%
Scientech Research LLC0.42%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.47%
VANGUARD EXTENDED MARKET INDEX FUND0.45%
U.S. VECTOR EQUITY PORTFOLIO0.09%
Dimensional U.S. Core Equity 2 ETF0.08%
Fidelity Series Total Market Index Fund0.08%
Omni Small-Cap Value Fund0.05%
U.S. Sustainability Core 1 Portfolio0.04%
Dimensional US Core Equity 1 ETF0.04%
U.S. Social Core Equity 2 Portfolio0.03%
Fidelity Total Market Index Fund0.02%

OakChart. KPRX. Cached 15 minutes.

Some panels did not load: ratings, insider.